Skip to main content
Erschienen in: Gastric Cancer 3/2019

01.05.2019 | Original Article

The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study

verfasst von: Xi Cheng, Shan Yu, Yan Wang, Yuehong Cui, Wei Li, Yiyi Yu, Cheng Tang, Huiqin Jiang, Yuan Ji, Yihong Sun, Xuefei Wang, Zhenbin Shen, Fenglin Liu, Tian-shu Liu

Erschienen in: Gastric Cancer | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

To compare the efficacy of oxaliplatin-based and oxaliplatin-free adjuvant chemotherapies in patients with different Lauren type gastric cancers after D2 gastrectomy.

Methods

From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed. Patients who received different adjuvant chemotherapy regimens were divided into two subgroups: oxaliplatin-based and oxaliplatin-free subgroup. Clinical outcomes were analyzed according to pathological stage and different Lauren types.

Results

From Jan 2010 to June 2017, a total of 580 patients met all the eligibility criteria and were enrolled. The median DFS for all the patients was 24.37 months and the median OS was 56.70 months. In patients with intestinal type gastric cancer, the median DFS of the oxaliplatin-based subgroup was significantly longer than that of oxaliplatin-free subgroup (48.73 vs. 18.33 months, P < 0.001). The median OS was not reached in the oxaliplatin-based subgroup and 54.33 months in the oxaliplatin-free subgroup (P = 0.006). In patients with diffuse type gastric cancer, neither DFS nor OS differed significantly between two subgroups. In multivariate analysis, oxaliplatin-based adjuvant chemotherapy was independent positive predictor of DFS (HR 0.40; 95% CI 0.28–0.59; P < 0.001) and OS (HR 0.35; 95% CI 0.20–0.62; P < 0.001) in patients with intestinal type gastric cancer.

Conclusions

The results of our study suggested that oxaliplatin-based adjuvant chemotherapy was more effective in patients with intestinal type gastric cancer after D2 gastrectomy but showed no more survival benefit in patients with diffuse type.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int Cancer. 2015;136(5):E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int Cancer. 2015;136(5):E359–86.CrossRef
2.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
4.
Zurück zum Zitat Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol. 1995;6(suppl_1):17–26.CrossRefPubMed Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol. 1995;6(suppl_1):17–26.CrossRefPubMed
5.
Zurück zum Zitat Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMed Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMed
6.
Zurück zum Zitat Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRef Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRef
7.
Zurück zum Zitat Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20(1):175–81.CrossRefPubMed Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20(1):175–81.CrossRefPubMed
8.
Zurück zum Zitat Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18(1):547.CrossRefPubMedPubMedCentral Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18(1):547.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Yang L, Yang YI, Qin Q, et al. Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer. Oncol Lett. 2015;9(3):1451–7.CrossRefPubMed Yang L, Yang YI, Qin Q, et al. Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer. Oncol Lett. 2015;9(3):1451–7.CrossRefPubMed
10.
Zurück zum Zitat Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRef Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRef
11.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed
12.
Zurück zum Zitat Fujitani K, Tamura S, Kimura Y, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2014;17(2):348–53.CrossRefPubMed Fujitani K, Tamura S, Kimura Y, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2014;17(2):348–53.CrossRefPubMed
13.
Zurück zum Zitat Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64(1):31–49.CrossRefPubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64(1):31–49.CrossRefPubMed
14.
Zurück zum Zitat Qiu M, Cai M, Zhang D, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11(1):58.CrossRefPubMedPubMedCentral Qiu M, Cai M, Zhang D, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11(1):58.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Liu L, Wang ZW, Ji J, et al. A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma. AntiCancer Agents Med Chem (Former Curr Med Chem AntiCancer Agents). 2013;13(2):227–234. Liu L, Wang ZW, Ji J, et al. A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma. AntiCancer Agents Med Chem (Former Curr Med Chem AntiCancer Agents). 2013;13(2):227–234.
16.
Zurück zum Zitat Tamura S, Fujitani K, Kimura Y, et al. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy. Oncology. 2011;80(5–6):296–300.CrossRefPubMed Tamura S, Fujitani K, Kimura Y, et al. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy. Oncology. 2011;80(5–6):296–300.CrossRefPubMed
17.
Zurück zum Zitat Hass HG, Smith U, Jäger C, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. Oncol Res Treat. 2011;34(12):682–6. Hass HG, Smith U, Jäger C, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. Oncol Res Treat. 2011;34(12):682–6.
18.
Zurück zum Zitat Chen L, Shi Y, Yuan J, et al. Evaluation of docetaxel-and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Med Oncol. 2014;31(9):159.CrossRefPubMed Chen L, Shi Y, Yuan J, et al. Evaluation of docetaxel-and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Med Oncol. 2014;31(9):159.CrossRefPubMed
19.
Zurück zum Zitat Yang XF, Yang L, Mao XY, et al. Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study. World J Gastroenterol. 2004;10(5):750.CrossRefPubMedPubMedCentral Yang XF, Yang L, Mao XY, et al. Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study. World J Gastroenterol. 2004;10(5):750.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yoon C, Cho SJ, Aksoy BA, et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 2015;22:971–983.CrossRefPubMedPubMedCentral Yoon C, Cho SJ, Aksoy BA, et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 2015;22:971–983.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46(6):583.CrossRef Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46(6):583.CrossRef
22.
Zurück zum Zitat Zheng Z, Jin X, He Q, et al. The efficacy of taxanes-and oxaliplatin-based chemotherapy in the treatment of gastric cancer after D2 Gastrectomy for different Lauren types. Medicine (Baltimore). 2016;95(6):e2785.CrossRef Zheng Z, Jin X, He Q, et al. The efficacy of taxanes-and oxaliplatin-based chemotherapy in the treatment of gastric cancer after D2 Gastrectomy for different Lauren types. Medicine (Baltimore). 2016;95(6):e2785.CrossRef
Metadaten
Titel
The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study
verfasst von
Xi Cheng
Shan Yu
Yan Wang
Yuehong Cui
Wei Li
Yiyi Yu
Cheng Tang
Huiqin Jiang
Yuan Ji
Yihong Sun
Xuefei Wang
Zhenbin Shen
Fenglin Liu
Tian-shu Liu
Publikationsdatum
01.05.2019
Verlag
Springer Singapore
Erschienen in
Gastric Cancer / Ausgabe 3/2019
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-018-0895-x

Weitere Artikel der Ausgabe 3/2019

Gastric Cancer 3/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.